<?xml version='1.0' encoding='utf-8'?>
<document id="32071055"><sentence text="Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir."><entity charOffset="0-8" id="DDI-PubMed.32071055.s1.e0" text="Abacavir" /><entity charOffset="63-73" id="DDI-PubMed.32071055.s1.e1" text="rifampicin" /><entity charOffset="102-111" id="DDI-PubMed.32071055.s1.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.32071055.s1.e0" e2="DDI-PubMed.32071055.s1.e0" /><pair ddi="false" e1="DDI-PubMed.32071055.s1.e0" e2="DDI-PubMed.32071055.s1.e1" /><pair ddi="false" e1="DDI-PubMed.32071055.s1.e0" e2="DDI-PubMed.32071055.s1.e2" /><pair ddi="false" e1="DDI-PubMed.32071055.s1.e1" e2="DDI-PubMed.32071055.s1.e1" /><pair ddi="false" e1="DDI-PubMed.32071055.s1.e1" e2="DDI-PubMed.32071055.s1.e2" /></sentence><sentence text="In children requiring co-formulated lopinavir/ritonavir-4:1 and rifampicin"><entity charOffset="36-45" id="DDI-PubMed.32071055.s2.e0" text="lopinavir" /><entity charOffset="64-74" id="DDI-PubMed.32071055.s2.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.32071055.s2.e0" e2="DDI-PubMed.32071055.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32071055.s2.e0" e2="DDI-PubMed.32071055.s2.e1" /></sentence><sentence text=" adding ritonavir to achieve a 4:4 ratio with lopinavir (LPV/r-4:4) overcomes the drug-drug interaction"><entity charOffset="8-17" id="DDI-PubMed.32071055.s3.e0" text="ritonavir" /><entity charOffset="46-55" id="DDI-PubMed.32071055.s3.e1" text="lopinavir" /><pair ddi="false" e1="DDI-PubMed.32071055.s3.e0" e2="DDI-PubMed.32071055.s3.e0" /><pair ddi="false" e1="DDI-PubMed.32071055.s3.e0" e2="DDI-PubMed.32071055.s3.e1" /></sentence><sentence text=" Possible drug-drug interactions within this regimen may affect abacavir concentrations, but this has never been studied"><entity charOffset="64-72" id="DDI-PubMed.32071055.s4.e0" text="abacavir" /></sentence><sentence text=" Children &lt;15 kg needing rifampicin and LPV/r-4:4 were enrolled in a pharmacokinetic study and underwent intensive pharmacokinetic sampling on 3 visits: a) during the intensive and b) continuation phase of anti-tuberculosis treatment with LPV/r-4:4, and c) one month after anti-tuberculosis treatment completion on LPV/r-4:1"><entity charOffset="25-35" id="DDI-PubMed.32071055.s5.e0" text="rifampicin" /></sentence><sentence text=" Pharmacometric modelling and simulation were used to compare exposures across weight bands with adult target exposures" /><sentence text=" Eighty-seven children median (inter-quartile range) age and weight of 19 (4-64) months and 8" /><sentence text="7 (3" /><sentence text="9-14" /><sentence text="9) kg respectively were included in the abacavir analysis"><entity charOffset="40-48" id="DDI-PubMed.32071055.s10.e0" text="abacavir" /></sentence><sentence text=" Abacavir pharmacokinetics was best described by a two-compartment model with first-order elimination and transit compartment absorption"><entity charOffset="1-9" id="DDI-PubMed.32071055.s11.e0" text="Abacavir" /></sentence><sentence text=" After allometric scaling adjusted for the effect of body size, maturation could be identified: clearance was predicted to be fully mature around two years of age and to reach half of this mature value around two months" /><sentence text=" Abacavir bioavailability decreased 36% during treatment with rifampicin and LPV/r-4:4 but remained within the median adult recommended exposure, except for the 3-4"><entity charOffset="1-9" id="DDI-PubMed.32071055.s13.e0" text="Abacavir" /><entity charOffset="62-72" id="DDI-PubMed.32071055.s13.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.32071055.s13.e0" e2="DDI-PubMed.32071055.s13.e0" /><pair ddi="false" e1="DDI-PubMed.32071055.s13.e0" e2="DDI-PubMed.32071055.s13.e1" /></sentence><sentence text="9 kg weight-band where exposures were higher" /><sentence text=" Observed pre-dose morning trough concentrations were higher than the evening values" /><sentence text=" Though abacavir exposure significantly decreased during concomitant administration of rifampicin and LPV/r-4:4, it remained within acceptable ranges"><entity charOffset="8-16" id="DDI-PubMed.32071055.s16.e0" text="abacavir" /><entity charOffset="87-97" id="DDI-PubMed.32071055.s16.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.32071055.s16.e0" e2="DDI-PubMed.32071055.s16.e0" /><pair ddi="false" e1="DDI-PubMed.32071055.s16.e0" e2="DDI-PubMed.32071055.s16.e1" /></sentence><sentence text=" (This study is registered in ClinicalTrials" /><sentence text="gov under identifier NCT02348177" /><sentence text=")" /><sentence text="" /></document>